Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC 관련 제품 (305):

Cat. No.	상품명	효과	Purity

HY-148820

Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT		98.65%
Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make an antibody agent conjugate (ADC), ABBV-969.

HY-155870A

DL-01 formic		98.46%
DL-01 formic is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.

HY-153180

PB038		98.99%
PB038 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.

HY-131057

Mc-VC-PAB-SN38
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).

HY-153892

Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide		99.79%
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is the drug-linker conjugate for ADC, containing ADC linker Gly-Mal-GGFG and ADC cytotoxin Deruxtecan 2-hydroxypropanamide.

HY-178275

Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol		98.26%
Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol (Example 9) is a conjugate of the ADC toxic molecule and the linker, where the toxic molecule part is Hydrotecan (HY-164378), and the linker part is Mc-Glu(D-Glucamine)-val-ala (HY-178309) .

HY-W590556

Endo-BCN-PEG4-Val-Cit-PAB-MMAF
Endo-BCN-PEG4-Val-Cit-PAB-MMAF is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-177879

2-MSP-5-HA-VA-PAB-Exatecan
2-MSP-5-HA-Val-Cit-PAB-Exatecan (A-24) is a drug-linker conjugate for ADC. 2-MSP-5-HA-Val-Cit-PAB-Exatecan consists of Exatecan (HY-13631) and a linker. 2-MSP-5-HA-Val-Cit-PAB-Exatecan can be used for synthesis of ADCs.

HY-164239

NH2-PEG3-VC-PAB-MMAE		99.10%
NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). NH2-PEG3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).

HY-15575G

VcMMAE (GMP)
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC.

HY-126687

Mal-PEG4-VC-PAB-DMEA-PNU-159682
Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.

HY-139642

Mal-(CH2)5-Val-Cit-PAB-Eribulin		99.01%
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.

HY-148057

TCO-PEG4-VC-PAB-MMAE		99.30%
TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162). TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

HY-136170

MC-SN38		99.09%
MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.

HY-164367

Mal-Bal-Ph(β-D-Glucose)-7-MAD-MDCPT		98.19%
DBCO-PEG2-C2-acid is an ADC Linker. DBCO-PEG2-C2-acid can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-154915

MC-EVCit-PAB-MMAE		99.04%
MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162).

HY-141833

Bi-Mc-VC-PAB-MMAE		98.43%
Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.

HY-170512

Mal-GGFG-PAB-MMAE		99.96%
Mal-GGFG-PAB-MMAE (Compound 8) is a drug-linker conjugate, which is composed of the mitotic inhibitor MMAE (HY-15162) and the linker Mal-GGFG-PAB. Mal-GGFG-PAB-MMAE can be used for synthesis of antibody-drug conjugate.

HY-W591408

DBCO-Val-Cit-PAB-MMAE		98.33%
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group.

HY-153032

Val-Ala-PAB-MMAE		99.72%
Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.

Name
이메일 *

	Sorry, but the email address you supplied was invalid.